New analyst brings experience in medical devices, neuroscience and biology.
Related Posts
- 58By Donna Mitchell-Magaldi, Nerac Analyst, On March 20, 2010, the revised Guideline; MedDev 2.7.1 Rev 3 Clinical Evaluation: A Guide for Manufacturers and Notified Bodies became a requirement for obtaining and maintaining a CE Mark for all classes of devices marketed in the European Union. An important component of the MedDev 2.7.1 Rev 3 is the…
- 57By Ron Sills, Nerac Analyst Originally Published: September 29th, 2014 The European Union’s Council Directive 93/42/EEC concerning medical devices contains the essential requirements to be met by medical device manufacturers in order to market their products in the 28 member countries. A technical file for Class IIa and IIb devices, or a design dossier for…
- 55New analyst brings extensive experience in the biotechnology industry, primarily in the areas of chemical and biochemical defense systems, electrochemical devices, nanotechnology, materials chemistry and physical-organic chemistry Read the full release here.